Purdue Pharma Settlement a “Stopgap” For Areas Hardest Hit by Opioid Crisis: Report

The proposed settlement with OxyContin maker Purdue Pharma is “no more than a stopgap for local and state governments,” which will continue to face costs related to the opioid crisis that far exceed the agreed upon amounts, according to a new report by Moody’s Investors Services.

Earlier this month, Purdue Pharma reached a tentative settlement worth billions of dollars to resolve thousands of lawsuits brought by state and local governments who sued the drug company for its role in the opioid epidemic.

The report states “the Purdue payoff is unlikely to reverse the economic and social woes related to high levels of opioid addiction for the foreseeable future,” according to State House News Service.

The report concluded the deal would help state and local governments, but would be unlikely to reverse the social or economic problems caused by opioids, especially in the areas hardest hit by the crisis.

A bankruptcy judge must approve the deal. Twenty-four state attorneys general have said they will not sign on to the deal.

Heroin & the Opioid Epidemic: From Understanding to Action

Heroin and other opioids are ravaging communities across America. Heroin-related deaths increased by more than five times between 2010 and 2017, and drug deaths from fentanyl and other synthetic opioids are seeing a sharp rise as well.


Leave a Comment

Please leave a comment below to contribute to the discussion. If you have a specific question, please contact a Parent Specialist, who will provide you with one-on-one help.

Your email address will not be published. Required fields are marked *